RBC Capital Downgrades Kymera Therapeutics to Sector Perform, Raises Price Target to $115
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsDowngradesPrice Target
RBC Capital analyst Brian Abrahams downgrades Kymera Therapeutics (NASDAQ:KYMR) from Outperform to Sector Perform and raises the price target from $106 to $115.
RBC Capital analyst Brian Abrahams downgrades Kymera Therapeutics (NASDAQ:KYMR) from Outperform to Sector Perform and raises the price target from $106 to $115.